Neurological Biomarkers Market Size to grow by USD 7.82 billion between 2024-2028
According to a research report “ Neurological Biomarkers Market” by End-user (Hospitals, Clinical diagnostic centers, Research organizations and others) Indication (AD, PD, ASD, MS, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 7.82 billion, at a CAGR of 13.01% during the forecast period. In the neurological biomarkers market, there is a significant demand for advanced diagnostic tools to identify and monitor neurological disorders such as epilepsy, stroke, Parkinson's disease, and brain tumors. These conditions pose a high risk of disability and mortality, with Parkinson's disease being a leading cause of neurological disease in the aging population. Factors contributing to these disorders include bacterial and viral infections, genetic factors, and immune response deficiencies. The Centers for Disease Control and Prevention (CDC) reports a prevalence increase from 1% to 4% in the 60-80 age group for Parkinson's disease alone. Accurate and timely diagnosis through neurological biomarkers is crucial for effective treatment and management of these debilitating conditions..
Browse market data tables, figures, and in-depth TOC on “Neurological Biomarkers Market” by End-user (Hospitals, Clinical diagnostic centers, Research organizations and others) Indication (AD, PD, ASD, MS, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By End-user, the Hospitals segment is projected to dominate the market size in 2024
Neurological biomarkers hold significant value in the healthcare industry, particularly for hospitals, which serve as major consumers. These institutions, including multispecialty hospitals and hospital groups, boast over 500 beds and cater to a large patient base. The escalating number of hospitalizations for neurological disorders will propel the demand for neurological biomarker products, thereby fueling market expansion. Medium-sized hospitals, with a restricted pool of supplier groups, often rely on external providers for medical equipment and laboratory testing services.
By Indication, AD segment is expected to hold the largest market size for the year 2024
Neurological biomarkers play a pivotal role in the early detection and diagnosis of Alzheimer's disease (AD). The diagnostic criteria for AD have evolved, integrating brain imaging and CSF biomarkers to identify individuals with progressing AD neuropathology. These biomarkers, including beta-amyloid plaques and tau neurofibrillary tangles, serve as effective indicators of the disease's onset before overt symptoms emerge. The Neurological Biomarkers Market is witnessing significant growth due to the increasing demand for early and accurate AD diagnosis.
North America is forecasted to hold the largest market size by region in 2024
The neurological biomarkers market is experiencing significant growth due to the rising prevalence of neurological disorders, particularly Alzheimer's disease. With an estimated 6.2 million Americans aged 65 and above living with Alzheimer's dementia in 2021, and this number projected to reach 13.8 million by 2060, the market demand is escalating. In 2019, Alzheimer's was the fifth-leading cause of death among Americans aged 65 and older, with 121,499 deaths recorded. This high prevalence, an aging population, substantial healthcare expenditure on neurological disease treatment, and favorable reimbursement policies for neuro-diagnostic procedures are key growth drivers for the market during the forecast period.
The Neurological Biomarkers Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
In the realm of neurology, the discovery and utilization of reliable biomarkers have emerged as a critical component in advancing healthcare provision. Neurological biomarkers encompass various substances found in body fluids, such as blood, that can aid in the interpretation of patient conditions related to neurological disorders. These conditions include, but are not limited to, Autism, Epilepsy, Brain tumors, Stroke, Dementia, and Alzheimer's Disease (AD). The application of neurological biomarkers holds significant importance in ensuring patient privacy while providing accurate treatment outcomes. These markers can serve as diagnostic tools for early detection and rapid blood tests for monitoring disease progression. Moreover, they play a pivotal role in the development and implementation of targeted therapies and precision medicine. Despite the promising potential of neurological biomarkers, challenges persist, including adverse effects and delayed clinical trials. Healthcare providers and physicians continue to explore innovative approaches to address these challenges and maximize the benefits of these valuable indicators for brain health.
Market Research Overview
In the rapidly evolving field of healthcare, neurological biomarkers have emerged as a critical area of research for pharmaceutical firms and clinical diagnostics. These biomarkers, which can be non-invasively derived through machine learning and artificial intelligence, play a pivotal role in personalised medicine and therapeutic research. Clinical validations are essential to ensure the reliability of these biomarkers, which include digital biomarkers derived from NeuraLight, microarray technology, and proteomic biomarkers. Neurological conditions such as Alzheimer's Disease (AD), Parkinson's disease, multiple sclerosis, epilepsy, and neurodegenerative diseases are prime targets for this research. Lifestyle-related factors, aging global population, and changing lifestyle habits also contribute to the growing demand for neurological biomarkers. Sample preparation, data analysis, and data interpretation are crucial laboratory techniques in the development of these biomarkers. Patient privacy and adverse effects are critical considerations in the clinical trials of neurological biomarkers. Healthcare providers and physicians look forward to the potential of targeted therapies and precision medicine offered by these biomarkers for conditions like stroke, brain tumors, and dementia.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
